Lin Wu

Central South University - Thoracic Medicine Department II

Changsha

China

SCHOLARLY PAPERS

9

DOWNLOADS

476

TOTAL CITATIONS

0

Scholarly Papers (9)

1.

Furmonertinib (AST2818) Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multi-Center, Double-Blind, Randomized Phase 3 Study (FURLONG)

Number of pages: 53 Posted: 10 Jan 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Harbin Medical University - Department of Medical Oncology, Xuzhou Central Hospital - Department of Medical Oncology, China Medical University - Department of Medical Oncology, Central South University - Thoracic Medicine Department II, The People's Hospital of Guangxi Zhuang Autonomous Region - Department of Medical Oncology, Xinjiang Medical University - Department of Pulmonary Medicine, Xuzhou Medical College - Department of Respiratory Medicine, Nantong Tumor Hospital - Department of Medical Oncology, Wenzhou Medical University - Department of Pulmonary and Critical Care Medicine, Dalian University - Department of Oncology, University of Science and Technology of China (USTC) - Department of Respiratory Medicine, Jilin Cancer Hospital - Department of Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Capital Medical University - Department of Oncology, Hebei University - Department of Medical Oncology, Jilin University (JLU) - Cancer Center, Nantong University - Department of Respiratory Medicine, Shanghai Allist Pharmaceutical Technology, Shanghai Allist Pharmaceutical Technology and Shanghai Allist Pharmaceutical Technology
Downloads 212 (295,386)

Abstract:

Loading...

Furmonertinib, AST2818, NSCLC, EGFR, TKI

2.

Sintilimab Plus Bevacizumab Biosimilar IBI305, and Chemotherapy for Patients with EGFR-Mutant Nonsquamous NSCLC Who Progressed on EGFR-TKI Therapy (ORIENT-31): Interim Results from a Randomized, Double-Blind, Phase 3 Study

Number of pages: 38 Posted: 18 Mar 2022
Shanghai Jiao Tong University (SJTU) - Shanghai Lung Cancer Center, Central South University - Thoracic Medicine Department II, Shanghai Jiao Tong University (SJTU) - Department of Medical Oncology, Jilin Cancer Hospital - Department of Oncology, Zhengzhou University - Henan Cancer Hospital, Peking University - Department of Thoracic Medical Oncology, Peking University - Department of Thoracic Medical Oncology, Huazhong University of Science and Technology - Hubei Cancer Hospital, Shandong First Medical University - Department of Oncology, Xuzhou Central Hospital, Nanjing University - Department of Respiratory Medicine, Hebei Medical University, Jilin University (JLU) - Cancer Center, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Zhengzhou University - Department of Oncology, Xiamen University, Nanjing University, Sichuan University - Department of Respiratory and Critical Care Medicine, Zhengzhou University - Henan Provincial People's Hospital, Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc. - Department of Biostatistics and Information, Eli Lilly and Company, Ltd - Department of Oncology Medical Strategy, Eli Lilly and Company, Ltd - Clinical Design, Delivery & Analytics, Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc. - Department of Biostatistics and Information and Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology
Downloads 95 (565,488)

Abstract:

Loading...

sintilimab, IBI305, NSCLC, EGFR

3.

Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (Choice-01): Final Os and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial

Number of pages: 37 Posted: 02 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Central South University - Thoracic Medicine Department II, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Jilin Cancer Hospital, China Medical University - Medical Oncology Department of Thoracic Cancer, Guangdong Pharmaceutical University - Department of Medical Oncology, Xuzhou Central Hospital, Jiangnan University - Affiliated Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Harbin Medical University, Wenzhou Medical University - Taizhou Hospital of Zhejiang Province, Linyi Cancer Hospital - Department of Medical Oncology, Zhejiang University - Second Affiliated Hospital, The First Affiliated Hospital of Guangxi Medical University, Shanghai Jiao Tong University (SJTU) - Department of Respiratory and Critical Care Medicine, Tangshan People’s Hospital, Shandong University - Shandong Cancer Hospital, Qingdao Central Hospital, ZhongDa Hospital of Southeast University, Huazhong University of Science and Technology - Department of Medical Oncology, Nanchang University - First Affiliated Hospital, Zhengzhou University - Henan Cancer Hospital, Government of the People's Republic of China - Second People's Hospital of Yibin, Peking University - Department of Thoracic Medical Oncology, Medical School of Nanjing University, Xiamen University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Zhengzhou University - Department of Oncology, Xinjiang Medical University - Affiliated Tumor Hospital, China Medical University - Department of Medical Oncology, Qingdao University - Affiliated Hospital, Nanchang University - Department of Medical Oncology, Shandong University - Qilu Hospital, Shanghai Pulmonary Hospital, Tianjin Medical University - Department of Medical Oncology, Nanjing University - Department of Respiratory Medicine, Anhui Provincial Cancer Hospital, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Guangzhou Medical University - Second Affiliated Hospital, Army Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Nantong Tumor Hospital - Department of Medical Oncology, First People's Hospital of Changzhou, Chongqing Medical University - Second Affiliated Hospital, Jilin University (JLU) - Cancer Center, Shanghai Jiao Tong University (SJTU) - Ruijin Hospital of Shanghai, Yangzhou University - Subei People's Hospital of Jiangsu Province, Anhui Provincial Cancer Hospital, Shanxi Provincial People's Hospital, Shanxi Provincial People's Hospital, Chinese Academy of Medical Sciences - Cancer Hospital, Nanjing Medical University - Nanjing First Hospital, Nanjing Medical University - Department of Oncology, ChangZhou Cancer Hospital, Nantong University - Department of Respiratory Medicine, First Hospital of Jiaxing, Fujian Provincial Cancer Hospital, Ground Force Medical University - Xinqiao Hospital, Xi’an Jiaotong University, Health Science Center, First Affiliated Hospital, TopAlliance Biosciences, TopAlliance Biosciences, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Shanghai Junshi Biosciences Co., LTD, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 45 (826,310)

Abstract:

Loading...

Non-small cell lung cancer, overall survival, immunotherapy, biomarker

4.

Epidemiology, Prevention, and Treatment of Chemotherapy-Induced Myelosuppression in China: A National Cross-Sectional Study

Number of pages: 29 Posted: 04 Jan 2024
Nanjing Medical University - Jiangsu Cancer Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Southern Medical University - Department of Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Xuzhou Medical University - Affiliated Hospital, Qingdao University - Affiliated Hospital, Hebei Medical University - Fourth Hospital, Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Central South University - Thoracic Medicine Department II, Xi'an Jiaotong University (XJTU), Second Affiliated Hospital, Peking University - Peking University Cancer Hospital & Institute, Peking University International Hospital, Jilin Cancer Hospital, Zhengzhou University, Shanghai Jiao Tong University (SJTU) - Department of Oncology, Anhui Medical University, Huazhong University of Science and Technology - Cancer Center, Tianjin Medical University - Tianjin Medical University Cancer Institute and Hospital, Shanxi Bethune Hospital, Harbin Medical University, Cancer Hospital, Department of Internal Medicine, Harbin Medical University, Cancer Hospital, Department of Internal Medicine, Fujian Medical University - Department of Thoracic Oncology, Guangxi Medical University - First Affiliated Hospital, University of Electronic Science and Technology of China (UESTC) - Sichuan Provincial People’s Hospital, Jiangxi Cancer Hospital, Hainan Cancer Hospital, Xinjiang Medical University - Affiliated Cancer Hospital, Kunming Medical University - Third Affifiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Sun Yat-sen University (SYSU), Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China and Nanjing Medical University - Jiangsu Cancer Hospital
Downloads 40 (865,723)

Abstract:

Loading...

Chemotherapy, Myelosuppression, Epidemiology, Prevention, Treatment, Cross-Sectional

5.

Rezivertinib Versus Gefitinib as First-Line Therapy for EGFR-Mutated Locally Advanced or Metastatic NSCLC Patients (REZOR): A Multicenter, Double-Blinded, Randomized Phase 3 Study

Number of pages: 26 Posted: 13 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Henan University of Science and Technology - Department of Medical Oncology, Zhengzhou University - Department of Oncology, Central South University - Thoracic Medicine Department II, People's Hospital of Deyang City, Shanxi Medical University - First Hospital, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Respiratory Medicine, Sichuan Cancer Hospital - Department of Medical Oncology, Chongqing University Cancer Hospital - Department of Palliative Care, Sichuan University - Department of Respiratory and Critical Care Medicine, Guangxi Medical University, Shandong First Medical University - Department of Oncology, Qingdao University - Yantai Yuhuangding Hospital, Fujian Medical University - Fujian Cancer Hospital, Shantou University - Department of Medical Oncology, Linyi Cancer Hospital - Department of Medical Oncology, Army Medical University - Institute of Cancer, Xingtai Medical College - Cancer Center, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Gannan Medical University - First Affiliated Hospital, Central South University - Department of Respiratory Medicine, University of South China, Central South University, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Xinjiang Medical University - Pulmonary Cancer Medicine, Hubei University of Arts and Science - Department of Oncology, Xinjiang Medical University, Zhengzhou University - Henan Provincial People's Hospital, Qingdao University - Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Jilin University (JLU) - Cancer Center, Peking University - Department of Thoracic Medical Oncology, Cangzhou Central Hospital, Xi'an Jiaotong University (XJTU), China Medical University - Liaoning Cancer Hospital & Institute, Xiangtan Central Hospital, Nankai University - Tianjin Chest Hospital, Nanjing Medical University - Department of Oncology, Xiamen University, Huazhong University of Science and Technology - Department of Medical Oncology, Zhejiang University - Key Laboratory of Respiratory Disease of Zhejiang Province, Henan University - Department of Oncology, Ningbo No. 2 Hospital, Zhengzhou University - Department of Medical Oncology, Shijiazhuang People’s Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Chifeng Municipal Hospital, Handan Central Hospital - Department of Oncology, Tianjin Medical University - The Second Hospital of Tianjin Medical University, Government of the People's Republic of China - Army Medical University, Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 27 (1,009,062)

Abstract:

Loading...

rezivertinib, gefitinib, NSCLC, EGFR TKI.

6.

Central Nervous System Efficacy of Rezivertinib (BPI-7711) in Advanced NCLC Patients with EGFR T790m Mutation: A Pooled Analysis of Two Clinical Trials

Number of pages: 33 Posted: 20 Mar 2023
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Shanxi Medical University - First Hospital, Shanxi Medical University - Department of Medical Oncology, Zhengzhou University - Department of Respiratory Medicine, Harbin Medical University - Department of Medical Oncology, Army Medical University - Institute of Cancer, Zhengzhou University - Department of Oncology, Sichuan University - Department of Respiratory and Critical Care Medicine, Linyi Cancer Hospital - Department of Medical Oncology, Zhengzhou University - Henan Provincial People's Hospital, Sichuan Cancer Hospital - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Peking University - Department of Thoracic Medical Oncology, Qingdao University - Yantai Yuhuangding Hospital, Zhejiang University - The First Affiliated Hospital, Central South University - Thoracic Medicine Department II, Bengbu Medical College - First Affiliated Hospital, Sichuan University - Department of Thoracic Oncology, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Guangdong Medical University - Department of Oncology, Shandong First Medical University - Department of Oncology, Chongqing University Cancer Hospital - Department of Palliative Care, Chongqing University Cancer Hospital, Soochow University - Department of Pulmonary and Critical Care Medicine, Xingtai Medical College - Cancer Center, Nanjing Medical University - Department of Oncology, People's Hospital of Deyang City - Department of Oncology, Xinjiang Medical University - Department of Pulmonary Medicine, Liuzhou People's Hospital - Department of Oncology, Dalian University - Department of Oncology, Central South University - Department of Respiratory Medicine, Henan University of Science and Technology - Department of Medical Oncology, Nanjing Medical University - Department of Respiratory Medicine, Government of the People's Republic of China - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Huazhong University of Science and Technology - Tongji Medical College, Henan University - Department of Oncology, China Medical University - Liaoning Cancer Hospital & Institute, Huazhong University of Science and Technology - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Department of Thoracic Surgery, Xuzhou Medical University - Department of Radiotherapy, Handan Central Hospital - Department of Oncology, Wenzhou Medical University - Second Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Medical Oncology, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Hubei University of Arts and Science - Department of Oncology, Zhejiang University - Key Laboratory of Respiratory Disease of Zhejiang Province, Shantou University - Department of Medical Oncology, Anhui Medical University - Department of Oncology, Soochow University - Second Affiliated Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 20 (1,067,294)

Abstract:

Loading...

Rezivertinib, BPI-7711, EGFR T790M mutation, CNS, NSCLC

7.

Efficacy and Safety of Envafolimab, Suvemcitug and Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer: An Open-Label Phase Ii Clinical Trial

Number of pages: 24 Posted: 10 Jan 2025
Jilin Cancer Hospital - Department of Oncology, Jilin Cancer Hospital, Central South University - Thoracic Medicine Department II, Shandong Provincial Cancer Hospital, affiliation not provided to SSRN, The First Affiliated Hospital of Zhengzhou University, affiliation not provided to SSRN, Anhui Medical University, affiliation not provided to SSRN, Anhui Provincial Cancer Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 17 (1,116,455)

Abstract:

Loading...

Non-small cell lung cancer, Suvemcitug, Anti-angiogenesis, Envafolimab, immune checkpoint inhibitor

8.

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent EGFR T790M Mutated NSCLC: A Phase IIb Study

Number of pages: 254 Posted: 11 May 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Shanxi Medical University - Department of Medical Oncology, Sichuan University - Department of Respiratory and Critical Care Medicine, Zhengzhou University - Henan Provincial People's Hospital, Sichuan Cancer Hospital - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Central South University - Thoracic Medicine Department II, Sichuan University - Department of Thoracic Oncology, Zhengzhou University - Department of Oncology, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Guangdong Medical University - Department of Oncology, Army Medical University - Institute of Cancer, Harbin Medical University - Department of Respiratory Medicine, Linyi Cancer Hospital - Department of Medical Oncology, Shandong First Medical University - Department of Oncology, Peking University - Department of Thoracic Medical Oncology, Xingtai Medical College - Cancer Center, People's Hospital of Deyang City - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Liuzhou People's Hospital - Department of Oncology, Dalian University - Department of Oncology, Central South University - Department of Respiratory Medicine, Zhengzhou University - Department of Respiratory Medicine, Henan University of Science and Technology - Department of Medical Oncology, Nanjing Medical University - Department of Respiratory Medicine, Government of the People's Republic of China - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Henan University - Department of Oncology, China Medical University - Liaoning Cancer Hospital & Institute, Huazhong University of Science and Technology - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Department of Thoracic Surgery, Handan Central Hospital - Department of Oncology, Wenzhou Medical University - Second Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Chongqing University Cancer Hospital - Department of Palliative Care, Xuzhou Medical University - Department of Radiotherapy, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Medical Oncology, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Hubei University of Arts and Science - Department of Oncology, Zhejiang University - Key Laboratory of Respiratory Disease of Zhejiang Province, Shantou University - Department of Medical Oncology, Nanjing Medical University - Department of Oncology, Anhui Medical University - Department of Oncology, Tongji University - Department of Respiratory and Critical Care Medicine, Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 13 (1,154,192)

Abstract:

Loading...

Rezivertinib, BPI-7711, NSCLC, EGFR T790M mutation, Third-generation EGFR TKI

9.

Effect of Trilaciclib Administered Before Chemotherapy in Patients with Extensive-Stage Small-Cell Lung Cancer: A Pooled Analysis of Four Randomized Studies

Number of pages: 34 Posted: 10 Aug 2024
affiliation not provided to SSRN, Central South University - Thoracic Medicine Department II, Tianjin Medical University - Tianjin Cancer Institute, Zhengzhou University - Henan Cancer Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Jilin Cancer Hospital - Department of Oncology
Downloads 7 (1,226,124)

Abstract:

Loading...

Trilaciclib, Chemotherapy-induced myelosuppression, Extensive-stage small-cell lung cancer, Severe neutropenia, Hematological toxicity